Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Accounts Payables (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Accounts Payables data on record, last reported at $4.3 million in Q4 2025.

  • For Q4 2025, Accounts Payables fell 49.99% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $4.3 million, down 49.99%, while the annual FY2025 figure was $4.3 million, 49.99% down from the prior year.
  • Accounts Payables reached $4.3 million in Q4 2025 per FHTX's latest filing, down from $9.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $10.1 million in Q3 2022 and bottomed at $2.9 million in Q1 2021.
  • Average Accounts Payables over 5 years is $6.3 million, with a median of $6.3 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: tumbled 60.78% in 2024, then skyrocketed 184.61% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $9.6 million in 2021, then crashed by 43.38% to $5.4 million in 2022, then grew by 15.63% to $6.3 million in 2023, then skyrocketed by 36.28% to $8.5 million in 2024, then crashed by 49.99% to $4.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $4.3 million in Q4 2025, $9.8 million in Q3 2025, and $3.3 million in Q2 2025.